Answers are grounded in this paper and cite their sources.
Introduction Pharmacovigilance has evolved from adverse‐event reporting into a multidisciplinary science concerned with detecting, evaluating, preventing and communicating medicine‐related harms across the product life cycle. Because pre authorisation clinical trials are usually limited in size, duration and population diversity, post‐authorisation safety assessment must draw on multiple evidence streams. Methods This conceptual review synthesises methodological, regulatory and scientific literature on pharmacovigilance evidence sources, including spontaneous reporting, clinical trial safety data, safety meta-analyses, disproportionality analyses, real‐world data, registries, patient‐reported evidence, computational methods, mechanistic evidence and regulatory judgement. Results The review proposes an evidence-based framework organised around eight interrelated domains: signal recognition, triage and benchmarking, clinical trial safety evidence, epidemiological evaluation, subgroup and registry evidence, mechanistic and translational evidence, patient-reported and digital evidence, and regulatory action and reassessment. Discussion The framework does not present causal assessment as a fixed linear sequence. Instead, it supports structured integration of complementary evidence, explicit acknowledgement of uncertainty, benefit‐risk contextualisation and continuing reassessment as new data emerge.
No takes yet. Share an insight, caveat, or question.
Mukoma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: